Jinwon Life Sciences "COVID-19 DNA Vaccine, Beta Variant Prevention Study Published in International Scientific Journal"

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 25th that it has published research results proving the immunogenicity and efficacy of the COVID-19 DNA vaccine (GLS-5310) in a hamster infection model in the international journal 'Frontiers in Virology.'

This study was conducted using the suction-type intradermal injector 'Gene-Derm' developed by GeneOne Life Science. The study explained that GLS-5310 prevented lung infections caused not only by the wild-type COVID-19 virus found in Wuhan but also by the Beta variant.

Gene-Derm is said to have advantages such as ease of use compared to other DNA vaccine delivery devices, low cost, minimal damage to the injection site, painless administration, and increased convenience for patient dosing.

A company official stated, "GLS-5310 was confirmed to form neutralizing antibodies that inhibit the binding of the receptor-binding domain (RBD) of both the wild-type and Delta strains and the 'ACE2' receptor. Although neutralizing antibodies inhibiting the RBD were not detected in the Beta strain, it was confirmed to prevent two variant viruses including the Beta strain. We also confirmed that the binding of the Beta strain RBD and ACE2 receptor was inhibited in the serum of experimental animals after intradermal and intranasal administration of GLS-5310, demonstrating the broad immunogenicity of GLS-5310."

Park Younggeun, CEO of GeneOne Life Science, said, "Considering the transition to the COVID endemic era, we aim to develop GLS-5310 as a differentiated booster-only vaccine targeting variant viruses. In South Korea, dosing of subjects in Phase 2a clinical trials has been completed, and in the United States, the first dosing in a clinical trial approved as a booster-only vaccine has been conducted."

This content was produced with the assistance of AI translation services.